Yamamoto Sunao, Okada Yosuke, Mori Hiroko, Fukumoto Seiji, Tanaka Yoshiya
The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan.
Intern Med. 2012;51(17):2375-8. doi: 10.2169/internalmedicine.51.7450. Epub 2012 Sep 1.
A 44-year-old woman with iron deficiency anemia was on a continuous course of intravenous saccharated ferric oxide (SFO). She came to our hospital because of right hip joint pain. She was found to have hypophosphatemia caused by impaired phosphorus resorption and her fibroblast growth factor 23 (FGF-23) levels were elevated. Therefore, she was diagnosed with FGF-23-related osteomalacia due to SFO administration. Discontinuation of the SFO treatment rapidly improved the impaired phosphorus resorption and also normalized the blood levels of phosphorus and FGF-23. During the treatment with SFO, it is important to regularly measure the blood levels of phosphorus in order to prevent the occurrence of osteomalacia.
一名患有缺铁性贫血的44岁女性正在接受持续的静脉注射含糖氧化铁（SFO）治疗。她因右髋关节疼痛前来我院就诊。检查发现她因磷吸收受损导致低磷血症，且成纤维细胞生长因子23（FGF - 23）水平升高。因此，她被诊断为因使用SFO导致的FGF - 23相关性骨软化症。停用SFO治疗后，磷吸收受损情况迅速改善，磷和FGF - 23的血液水平也恢复正常。在使用SFO治疗期间，定期测量血磷水平对于预防骨软化症的发生很重要。
